Reducing vein-to-vein time for cell therapy

The vein-to-vein journey in CAR-T cell therapy — from collecting a patient’s T cells to reinfusing the engineered CAR-T product — can span several weeks, during which patients may deteriorate or become ineligible for treatment. Reducing this timeline is critical to improve patient outcomes, reduce costs, and enable broader access to life-saving therapies.

This event invites innovators to present solutions that can help shorten the vein-to-vein timeline and improve scalability through e.g. automation of manual processes, and improvement of quality control and release testing.

Join experts from Cellular Origins, NanoCell Tx, NecstGen and SymCel as well as Johnson & Johnson to explore innovation and collaboration in this space.

Start-ups, early innovators and entrepreneurs are welcome to register here https://veintovein.splashthat.com/nl.

We also welcome stakeholders supporting these start-ups.

Location: Utrecht